Keith Simmon

Title: Innovations of Keith Simmon in Antitumor Research

Introduction

Keith Simmon is an accomplished inventor based in West Valley City, UT (US). He has made significant contributions to the field of antitumor research, particularly through his innovative work on quinoxaline derivatives. His research focuses on developing methods to enhance the effectiveness of cancer treatments.

Latest Patents

Keith Simmon holds a patent for "Quinoxaline derivatives as antitumor agents." This invention relates to methods of screening for binding partners that are essential for the biological activity of erastin, specifically targeting VDACs such as VDAC3. The patent also provides reagents and methods for effectively killing cancer cells using erastin and its related compounds or derivatives. He has 1 patent to his name.

Career Highlights

Simmon is currently associated with Prolexys Pharmaceuticals, Inc., where he continues to advance his research in cancer therapeutics. His work has the potential to significantly impact the treatment of various cancers, making him a valuable asset in the pharmaceutical industry.

Collaborations

Throughout his career, Keith has collaborated with notable colleagues, including Robert R. Becklin and Cindy Lou Chepanoske. These collaborations have fostered a productive environment for innovation and research in antitumor therapies.

Conclusion

Keith Simmon's contributions to antitumor research through his innovative patents and collaborations highlight his commitment to advancing cancer treatment. His work continues to inspire and pave the way for future developments in the field.